Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cullgen Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.cullgen.com/
Year Founded: 2018
Status: Private
BioCentury | Dec 5, 2024
Discovery & Translation
Science Spotlight: Advances in RSV and hMVP vaccines
BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Aug 8, 2023
Data Byte
How Astellas’ recent deals fit its focus areas
Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas
BioCentury | Jun 15, 2023
Deals
June 15 Quick Takes: Astellas adds protein degraders in Cullgen deal
Plus: Zentalis, Editas are latest to tap investors for follow-on cash and updates from AbbVie, Mersana, Nordic Bioscience, Aldeyra, Theradaptive
BioCentury | May 13, 2023
Deals
May 12 Quick Takes: AZ latest pharma to gain rights to a LaNova ADC
Plus: FDA clears Astellas’ therapy for hot flashes updates from Cullgen and SFJ-Serb
BioCentury | Oct 26, 2022
Management Tracks
With Connor leaving, GSK reorganizes roles in vaccine division
Plus Twist promotes Finn and updates from Nimbus, Enveda, X4 and more
BioCentury | Oct 23, 2020
Product Development
What’s next for targeted protein degradation
As the technology goes mainstream, next-gen molecules will use new enzymes, tap new pathways, and address PK/PD challenges
BioCentury | Nov 14, 2019
Emerging Company Profile
Cedilla: degrading proteins by modulating protein stability
How Cedilla harnesses native destabilization mechanisms to degrade proteins
BioCentury | Oct 23, 2019
Clinical News
Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic
BioCentury | Sep 6, 2019
Emerging Company Profile
Cullgen: boosting the breadth of E3 ligases for protein degradation
How Cullgen is expanding the repertoire of E3 ligases used in protein degradation
Items per page:
1 - 10 of 15